华森制药
(002907)
| 流通市值：49.31亿 | | | 总市值：68.65亿 |
| 流通股本：3.00亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 284,553,384.23 | 297,078,384.94 | 456,552,929.38 | 271,460,383.5 |
| 交易性金融资产 | 240,988,054.8 | 250,499,397.25 | 120,606,082.18 | 200,414,493.13 |
| 应收票据及应收账款 | 309,601,482.71 | 323,172,398.54 | 272,703,800.2 | 301,085,737.88 |
| 其中：应收票据 | 97,493,415.05 | 102,183,107.59 | 97,861,218.9 | 88,042,735.91 |
| 应收账款 | 212,108,067.66 | 220,989,290.95 | 174,842,581.3 | 213,043,001.97 |
| 预付款项 | 44,282,952.09 | 7,324,738.64 | 7,884,495.06 | 5,714,297.89 |
| 其他应收款合计 | 4,416,753.5 | 4,585,305.96 | 2,891,877.67 | 4,468,387.93 |
| 存货 | 120,784,309.42 | 127,823,788.51 | 140,125,411.63 | 149,299,692.71 |
| 其他流动资产 | 83,022,406.66 | 80,871,549.17 | 30,579,915.16 | 81,534,374.64 |
| 流动资产合计 | 1,088,649,343.41 | 1,091,355,563.01 | 1,031,344,511.28 | 1,013,977,367.68 |
| 非流动资产: | | | | |
| 长期股权投资 | 0 | 14,188,853.36 | 15,414,034.45 | 18,570,090.07 |
| 其他非流动金融资产 | 76,919,000 | 78,234,500 | 78,234,500 | 72,728,627.97 |
| 投资性房地产 | 66,157,296.78 | 67,054,591.2 | 68,327,959.4 | 68,656,482.27 |
| 固定资产 | 501,092,380.68 | 511,681,804.16 | 527,896,179.7 | 530,437,896.82 |
| 在建工程 | 9,280,829.79 | 10,529,968.44 | 10,190,518.9 | 23,460,639.23 |
| 使用权资产 | 296,022.41 | 270,427.16 | 143,168.7 | 144,670.21 |
| 无形资产 | 214,779,462.58 | 121,085,857.35 | 125,888,406.4 | 123,736,741.26 |
| 开发支出 | 33,610,008.64 | 32,362,755.51 | 30,270,209.78 | 32,586,467.54 |
| 长期待摊费用 | 9,007,897.75 | 6,519,283.04 | 6,699,093.67 | 7,449,833.21 |
| 递延所得税资产 | 15,176,926.25 | 14,922,852.61 | 17,256,757.2 | 14,169,986.85 |
| 其他非流动资产 | 5,763,843.14 | 5,355,936.63 | 5,884,249.52 | 5,797,494.35 |
| 非流动资产合计 | 932,083,668.02 | 862,206,829.46 | 886,205,077.72 | 897,738,929.78 |
| 资产总计 | 2,020,733,011.43 | 1,953,562,392.47 | 1,917,549,589 | 1,911,716,297.46 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 73,468,962.62 | 68,465,269.6 | 64,363,225.38 | 73,596,084.42 |
| 应付账款 | 73,468,962.62 | 68,465,269.6 | 64,363,225.38 | 73,596,084.42 |
| 预收款项 | 1,145,275.85 | 946,377.5 | 1,047,147.07 | 1,190,670.23 |
| 合同负债 | 10,802,634.02 | 4,550,742.76 | 8,688,989.46 | 4,119,518.65 |
| 应付职工薪酬 | 9,669,969.91 | 8,013,586.9 | 25,313,927.98 | 7,963,539.76 |
| 应交税费 | 7,340,347.15 | 18,759,671.62 | 11,797,879.99 | 13,207,096.1 |
| 其他应付款合计 | 114,640,789.85 | 108,523,465.25 | 99,573,492.18 | 106,685,525.68 |
| 一年内到期的非流动负债 | 38,137,252.38 | 86,841.42 | 86,841.42 | 105,163.24 |
| 其他流动负债 | 1,424,933.81 | 598,423.17 | 1,162,637.44 | 664,735.32 |
| 流动负债合计 | 256,630,165.59 | 209,944,378.22 | 212,034,140.92 | 207,532,333.4 |
| 非流动负债: | | | | |
| 租赁负债 | 156,587.65 | 155,900.21 | 40,720.14 | 44,518.1 |
| 递延收益 | 40,368,019.6 | 40,906,749.8 | 42,992,848.24 | 45,078,946.68 |
| 递延所得税负债 | 14,719,828.92 | 2,058,277.14 | 2,483,601.32 | 1,783,184.79 |
| 非流动负债合计 | 55,244,436.17 | 43,120,927.15 | 45,517,169.7 | 46,906,649.57 |
| 负债合计 | 311,874,601.76 | 253,065,305.37 | 257,551,310.62 | 254,438,982.97 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 417,596,314 | 417,596,314 | 417,596,314 | 417,596,314 |
| 资本公积 | 451,038,872.02 | 459,480,719.05 | 459,331,051.85 | 459,181,384.65 |
| 其他综合收益 | 160,590.06 | 172,255.78 | 178,326.64 | -239,580.56 |
| 盈余公积 | 101,260,953.57 | 101,260,953.57 | 101,260,953.57 | 92,966,643.89 |
| 未分配利润 | 714,702,333.05 | 721,986,844.7 | 681,631,632.32 | 687,772,552.51 |
| 归属于母公司股东权益合计 | 1,684,759,062.7 | 1,700,497,087.1 | 1,659,998,278.38 | 1,657,277,314.49 |
| 少数股东权益 | 24,099,346.97 | - | - | - |
| 股东权益合计 | 1,708,858,409.67 | 1,700,497,087.1 | 1,659,998,278.38 | 1,657,277,314.49 |
| 负债和股东权益合计 | 2,020,733,011.43 | 1,953,562,392.47 | 1,917,549,589 | 1,911,716,297.46 |
| 公告日期 | 2025-08-22 | 2025-04-25 | 2025-04-25 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |